KR970706830A - 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna) - Google Patents

2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna)

Info

Publication number
KR970706830A
KR970706830A KR1019970703171A KR19970703171A KR970706830A KR 970706830 A KR970706830 A KR 970706830A KR 1019970703171 A KR1019970703171 A KR 1019970703171A KR 19970703171 A KR19970703171 A KR 19970703171A KR 970706830 A KR970706830 A KR 970706830A
Authority
KR
South Korea
Prior art keywords
composition
cisplatin
dithio
bis
ethanesulfonate
Prior art date
Application number
KR1019970703171A
Other languages
English (en)
Other versions
KR100411380B1 (ko
Inventor
허만 하우쉬어 프레드릭
하리다스 코차트
무라리 다나바란
가우라바람 레디 다샤라타
시타라무루 페다이아가리
Original Assignee
허만 하우쉬어 프레드릭
바이오누머릭 파마슈티칼스, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허만 하우쉬어 프레드릭, 바이오누머릭 파마슈티칼스, 인코오포레이티드 filed Critical 허만 하우쉬어 프레드릭
Publication of KR970706830A publication Critical patent/KR970706830A/ko
Application granted granted Critical
Publication of KR100411380B1 publication Critical patent/KR100411380B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

시스플라턴을 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용 형태와 함께 투여하는 것은 시스플라틴의 신독성과 골수억제를 감소시키며 시스플라틴의 항암작용을 감소시킨다. 바람직하게는 시스플라틴과 설포네이트는 조성물, 특히 염소 이온과 나트륨 및 수소 양이온을 함유하는 살균된 주사가능한 용액으로 제제화된다.

Description

2,2'-디티오-비스(에탄설포네이트) (디메스나)와 조합된 시스플라틴의 조성물(COMPOSITION OF CISPLATIN IN COMBINATION WITH 2,2'-DITHIO-BIS (ETHANESULFONATE)(DIMESNA)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 시스플라틴과 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용 형태를 포함하는, 암환자에게 투여하기에 적합한 조성물.
  2. 제1항에 있어서, pH 2 내지 6의 살균된 주사가능한 수용액 또는 현탁액 형태의 조성물.
  3. 제2항에 있어서, pH가 4 내지 6인 조성물.
  4. 제2항 또는 3항에 있어서, 추가로 완충용액을 포함하는 조성물.
  5. 제2,3,4항에 있어서, 염소 음이온과 나트륨 양이온 및 수소 양이온을 포함하는 조성물.
  6. 제5항에 있어서, 0.1 내지 1.0㎎/㎖의 시스플라틴, 1.0 내지 320㎎/㎖의 설포네이트, 10 내지 25㎎/㎖의 염화나트륨 및 정의된 pH를 제공하기 위한 염산 또는 인산을 포함하는 조성물.
  7. 제6항에 있어서, 추가로 10 내지 25㎎/㎖의 만니톨을 포함하는 조성물.
  8. 제1,2,3,4,5,6 또는 7항에 있어서, 동결건조물 형태의 조성물.
  9. 환자의 혈액에 시스플라틴과 설포네이트가 공존하도록 시스플라틴과 함께 거의 동시에 또는 순차적으로 환자에게 투여하기 위한 약제의 제조에서 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용형태의 이용.
  10. 제9항에 있어서, 설포네이트의 수용액의 동결건조 형태의 이용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703171A 1994-11-14 1995-11-14 시스플라틴과2,2'-디티오-비스(에탄설포네이트)(디메스나)를포함하는조성물 KR100411380B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/338,379 US5789000A (en) 1994-11-14 1994-11-14 Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US08/338,379 1994-11-14

Publications (2)

Publication Number Publication Date
KR970706830A true KR970706830A (ko) 1997-12-01
KR100411380B1 KR100411380B1 (ko) 2004-04-30

Family

ID=23324592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703171A KR100411380B1 (ko) 1994-11-14 1995-11-14 시스플라틴과2,2'-디티오-비스(에탄설포네이트)(디메스나)를포함하는조성물

Country Status (13)

Country Link
US (5) US5789000A (ko)
EP (1) EP0792154B1 (ko)
JP (3) JP4171526B2 (ko)
KR (1) KR100411380B1 (ko)
CN (2) CN101987111A (ko)
AT (1) ATE237337T1 (ko)
AU (1) AU706181B2 (ko)
CA (1) CA2202170C (ko)
DE (1) DE69530412T2 (ko)
DK (1) DK0792154T3 (ko)
ES (1) ES2191717T3 (ko)
PT (1) PT792154E (ko)
WO (1) WO1996014852A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6025488A (en) * 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6037336A (en) * 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
WO1998011898A1 (en) * 1996-09-23 1998-03-26 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6197831B1 (en) * 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6034126A (en) * 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6156350A (en) * 1999-12-02 2000-12-05 Corazon Technologies, Inc. Methods and kits for use in preventing restenosis
CA2406081C (en) 2000-04-26 2009-12-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
KR20030065502A (ko) * 2000-11-02 2003-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
CA2434270A1 (en) * 2001-01-19 2002-07-25 Bionumerik Pharmaceuticals, Inc. Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002326356A1 (en) * 2001-07-09 2003-01-29 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US6352979B1 (en) * 2001-08-20 2002-03-05 Lucinda Lizcano Method of treating snakebite and complications resulting therefrom
IL160960A0 (en) * 2001-09-24 2004-08-31 Tosk Inc Reduced toxicity cisplatin formulations and methods for using the same
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
JP2006506945A (ja) * 2002-03-28 2006-03-02 メディカル・カレッジ・オブ・オハイオ 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) * 2002-07-10 2004-01-22 Frederick Hausheer Formulations and methods of reducing toxicity of anti-infective agents
WO2004058274A1 (en) * 2002-12-21 2004-07-15 Bionumerik Pharmaceuticals, Inc. Method of treating patients exposed to toxic chemical agents
EP2260846B1 (en) * 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
WO2005058005A2 (en) * 2003-12-17 2005-06-30 Bionumerik Pharmaceuticals, Inc. Process for synthesizing disulfides
WO2005095459A2 (en) * 2004-03-29 2005-10-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US7282602B2 (en) * 2004-09-21 2007-10-16 Bionumerik Pharmaceuticals, Inc. Medicinal disulfide salts
US7235589B2 (en) 2004-09-21 2007-06-26 Bio Numerik Pharmaceuticals, Inc. Method of treating patients undergoing kidney dialysis
US20060063742A1 (en) * 2004-09-21 2006-03-23 Hausheer Frederick H Method of treatment for or protection against lymphedema
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
DK1991237T3 (en) * 2005-12-13 2015-04-27 Bionumerik Pharmaceuticals Inc Chemoprotective methods and compositions
CA2647297A1 (en) * 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
CA2677639A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
WO2009039190A1 (en) * 2007-09-17 2009-03-26 Gene Express, Inc. Cancer risk biomarker
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US20110052581A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals Inc. Use of picoplatin and cetuximab to treat colorectal cancer
DK2249825T3 (en) * 2008-03-14 2016-01-11 Bionumerik Pharmaceuticals Inc Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667885B2 (ja) * 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 化学的保護方法及び組成物
CA2718233A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
BR112014017833A2 (pt) 2012-01-20 2021-03-23 Dennis Brown Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
MX2015000810A (es) * 2012-07-19 2015-06-05 Relypsa Inc Composiciones que comprenden polímeros reticulados con enlace a cationes.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2806866C3 (de) * 1978-02-17 1981-02-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
EP0334083B1 (de) * 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

Also Published As

Publication number Publication date
JPH10509143A (ja) 1998-09-08
US5902610A (en) 1999-05-11
US5866615A (en) 1999-02-02
US5789000A (en) 1998-08-04
AU706181B2 (en) 1999-06-10
CA2202170A1 (en) 1996-05-23
US5866617A (en) 1999-02-02
JP2008133304A (ja) 2008-06-12
CA2202170C (en) 2007-04-10
ATE237337T1 (de) 2003-05-15
PT792154E (pt) 2003-09-30
MX9703460A (es) 1997-07-31
JP2012211198A (ja) 2012-11-01
DE69530412T2 (de) 2003-10-30
KR100411380B1 (ko) 2004-04-30
JP4171526B2 (ja) 2008-10-22
DE69530412D1 (de) 2003-05-22
WO1996014852A1 (en) 1996-05-23
ES2191717T3 (es) 2003-09-16
EP0792154A1 (en) 1997-09-03
CN1165483A (zh) 1997-11-19
AU4116896A (en) 1996-06-06
US5866169A (en) 1999-02-02
CN1165483B (zh) 2012-09-05
EP0792154B1 (en) 2003-04-16
CN101987111A (zh) 2011-03-23
DK0792154T3 (da) 2003-08-04

Similar Documents

Publication Publication Date Title
KR970706830A (ko) 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna)
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
CO4700482A1 (es) Formulaciones de un analogo monomero de insulina
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
DE3772521D1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
BR9815159A (pt) Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio
BR9508554A (pt) Preparação farmaceuticamente estável de oxaliplatina
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
KR880007514A (ko) 키놀린 화합물
TR200101633T2 (tr) Farmasötik bileşim
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
IE81029B1 (en) Medicine based on neutralized sulphur derivatives
BR9712197A (pt) Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.
KR920004387A (ko) 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘
FR2427097A1 (fr) Medicament sous la forme d'une solution aqueuse sterile stable de cisplatine
GEP20043254B (en) Use of Camptothecin Derivatives with Reduced Gastrointestinal Toxicity
KR970706844A (ko) 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor)
EP1417970B1 (en) Anti-allergic, anti-bacteric and anti-redden compound for eyes
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
HUP0105359A2 (hu) Benzamidszármazékok és az azokat tartalmazó gyógyszerkészítmények
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121123

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20131122

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20141121

Year of fee payment: 12